ClinicalTrials.gg

Program

MI078

A development code. Also written as “MI078 capsule”, “MI078 capsule dose 1” and “MI078 capsule dose 2”.

Its studies are mostly in Depression, Postpartum, led by Nanjing Minova Pharmaceutical.

Furthest: phase 3, since Jul 10, 20263 company-led studies, 1 open or runningNext primary completion: Dec 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Nanjing Minova Pharmaceutical31 open or runningphase 3since Jul 10, 2026Apr 24, 2025Dec 2027phase 3 · NCT07721961

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 24, 2025First study: phase 1 study in Depression, PostpartumFirst studyNCT06982651 · 98 enrolled · China
  2. Apr 28, 2025Phase 2 study in Depression, PostpartumNCT06963580 · 72 enrolled · China
  3. Jul 10, 2026Phase 3 study in Depression, PostpartumPhase 3 reachedNCT07721961 · 200 planned · China

Ahead

  1. Dec 2027Primary completion: phase 3 study in Depression, PostpartumNCT07721961

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07721961Depression, Postpartum · China3RecruitingDec 2027200
NCT06963580Depression, Postpartum · China2CompletedAug 7, 202572
NCT06982651Depression, Postpartum · China1CompletedMar 18, 202498

How it is read

Names in the registry

  • “MI078 capsule”, 1 entry
  • “MI078 capsule dose 1”, 1 entry
  • “MI078 capsule dose 2”, 1 entry
  • “MI078”, 1 entry

Codes read as this program: MI078.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.